Last updated: August 24, 2026
Yeztugo, Gilead Sciences’ twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis, has the potential to become a multibillion-dollar HIV prevention product. Its commercial case depends on four variables: uptake among people who do not persist with daily oral PrEP, payer willingness to reimburse a high-cost preventive medicine, injection-site administration capacity, and the timing of competing long-acting products.
The product’s principal advantage is dosing frequency. Yeztugo reduces HIV prevention from daily adherence to two scheduled injections per year. Its principal commercial risk is price. A high annual cost could restrict access through prior authorization, specialty pharmacy controls, or public-program budget limits.
What is Yeztugo and what did the FDA approve?
Yeztugo is the brand name for lenacapavir, a long-acting HIV-1 capsid inhibitor developed by Gilead Sciences. The FDA approved Yeztugo in June 2025 for HIV-1 pre-exposure prophylaxis in adults and adolescents weighing at least 35 kilograms who are HIV-negative and at risk of sexually acquiring HIV, in combination with HIV testing and other required clinical monitoring (U.S. Food and Drug Administration [FDA], 2025).
The regimen uses:
- Two subcutaneous injections administered every six months.
- Oral lenacapavir tablets during initiation.
- HIV testing before each dose and during treatment.
- Administration by a healthcare professional rather than self-injection.
Yeztugo is distinct from Sunlenca, Gilead’s lenacapavir product for heavily treatment-experienced adults with multidrug-resistant HIV. Sunlenca is used with an optimized background regimen for treatment, while Yeztugo is used in people who do not have HIV.
What clinical evidence supports Yeztugo?
The PURPOSE 1 and PURPOSE 2 studies produced the core efficacy evidence.
| Study |
Population |
Result |
| PURPOSE 1 |
Cisgender women and adolescent girls in Uganda and South Africa |
Zero HIV infections in the lenacapavir group during the primary analysis |
| PURPOSE 2 |
Cisgender men, transgender women, transgender men and gender-diverse participants in multiple countries |
Zero HIV infections among participants receiving lenacapavir during the primary analysis |
The comparator arms included background oral PrEP regimens. The studies showed that long-acting administration can address adherence barriers that reduce the effectiveness of daily tablets in routine use (Gilead Sciences, 2024a, 2024b).
The regulatory value of the data is practical rather than limited to virologic potency. Oral tenofovir-based PrEP can be highly effective when taken consistently, but persistence, stigma, privacy concerns, pill fatigue, and unstable access reduce real-world protection. Yeztugo targets those implementation problems.
How large is the Yeztugo market?
The addressable market is larger than the number of people currently receiving PrEP. The commercial opportunity includes:
- People who have never started oral PrEP.
- Former users who discontinued because of adherence or stigma.
- Current users seeking less frequent dosing.
- People with unstable housing, travel schedules, or medication access.
- Public-health programs seeking higher protection rates in populations with low persistence.
The U.S. market is the initial commercial anchor because it has established HIV prevention reimbursement, extensive infectious-disease infrastructure, and high pharmaceutical spending. International demand may be larger in population terms but will generate lower revenue per patient because public-sector and global-health pricing will likely be substantially below U.S. commercial pricing.
What is the current HIV PrEP competitive landscape?
| Product |
Active ingredient |
Dosing |
Manufacturer |
Commercial position |
| Yeztugo |
Lenacapavir |
Every six months |
Gilead |
Longest dosing interval among approved PrEP products |
| Apretude |
Cabotegravir |
Every two months after initiation |
ViiV Healthcare |
Established long-acting injectable competitor |
| Truvada and generics |
TDF/emtricitabine |
Daily oral |
Multiple manufacturers |
Low-cost standard |
| Descovy |
TAF/emtricitabine |
Daily oral |
Gilead |
Branded oral option with a differentiated safety profile in selected populations |
| Generic TDF/FTC |
Tenofovir disoproxil fumarate/emtricitabine |
Daily oral |
Multiple manufacturers |
Primary price competitor |
Yeztugo has a dosing-frequency advantage over Apretude, but Apretude has an established regulatory and commercial position. Oral generics will remain the main price constraint.
What is Yeztugo’s price and revenue potential?
Gilead announced a U.S. wholesale acquisition cost of approximately $28,218 per year for Yeztugo, based on two six-month injections. The list price is not the same as net revenue. Commercial discounts, Medicaid rebates, 340B pricing, patient assistance, government procurement and specialty-distribution fees will reduce realized revenue (Gilead Sciences, 2025).
Yeztugo revenue scenarios
The following scenarios are analytical estimates based on U.S. patient penetration and net annual revenue. They are not Gilead guidance.
| Scenario |
U.S. treated patients |
Estimated net revenue per patient |
Estimated annual U.S. revenue |
| Early adoption |
75,000 |
$10,000-$15,000 |
$0.75-$1.13 billion |
| Base commercial case |
200,000 |
$12,000-$17,000 |
$2.4-$3.4 billion |
| Strong uptake |
400,000 |
$14,000-$19,000 |
$5.6-$7.6 billion |
A global opportunity would add volume but not necessarily comparable revenue. In low- and middle-income countries, Gilead’s voluntary licensing and access agreements are likely to reduce per-patient economics while supporting broader population coverage.
The most realistic financial trajectory is likely to have three stages:
2025-2026: Launch and access formation
Initial sales will depend on payer policy, provider education, injection logistics, and HIV testing protocols. Early prescriptions are likely to concentrate in specialist clinics, community health centers, sexually transmitted infection clinics and public-health programs.
Revenue in this stage may be constrained by:
- Prior authorization.
- Slow provider adoption.
- Injection scheduling requirements.
- Limited reimbursement codes.
- Patient transitions from oral PrEP.
- Distribution and cold-chain or specialty-pharmacy logistics.
2027-2029: Expansion and product substitution
If reimbursement improves and providers adopt twice-yearly prevention, Yeztugo could take share from Apretude and branded oral products. The primary growth pool would be people who are eligible for PrEP but are not currently protected.
This period will also show whether Yeztugo expands the market or mainly shifts patients from Gilead’s own oral products. Cannibalization of Descovy and other Gilead HIV prevention revenue would reduce the net incremental value of Yeztugo.
2030 onward: Mature market and pricing pressure
Mature revenue will depend on:
- Generic oral PrEP pricing.
- Long-acting competitors.
- Patent and regulatory exclusivity.
- Public-health procurement terms.
- Persistent adherence advantages in real-world use.
- New HIV prevention technologies.
Yeztugo could become a major Gilead product even if its revenue is lower than the company’s leading treatment products. Its value would increase if it produces durable retention and reduces HIV incidence in payer populations.
How does Yeztugo compare with Apretude?
Yeztugo’s main branded competitor is Apretude, which uses cabotegravir and requires injections approximately every two months after initiation. Yeztugo’s six-month interval reduces clinic visits and may lower administration burden.
| Commercial factor |
Yeztugo |
Apretude |
| Injection interval |
Six months |
Two months after initiation |
| Manufacturer |
Gilead Sciences |
ViiV Healthcare |
| Primary differentiation |
Longest dosing interval |
Established long-acting PrEP platform |
| Main operational risk |
Missed six-month follow-up and resistance management |
Frequent injection visits |
| Main payer issue |
High annual cost |
High acquisition and administration cost |
| Likely competitive segment |
Patients prioritizing convenience and persistence |
Patients already established on injectable PrEP |
Apretude’s earlier launch gives ViiV provider relationships and operational experience. Yeztugo’s longer interval is more likely to win through convenience than through a materially different prevention mechanism.
What is Yeztugo’s FDA regulatory and exclusivity position?
Yeztugo has FDA approval for HIV prevention, while Sunlenca has a separate treatment indication. The FDA approval establishes the product’s regulatory pathway but does not eliminate post-approval risks.
Important regulatory issues include:
- HIV testing before dosing.
- Management of inadvertent use during undiagnosed infection.
- Long pharmacokinetic persistence after discontinuation.
- Resistance risk if infection occurs during declining drug concentrations.
- Injection-site reactions.
- Drug-drug interactions involving lenacapavir metabolism and transport pathways.
- Pediatric and adolescent implementation.
Because lenacapavir remains in the body for extended periods, delayed diagnosis could create a period of functional monotherapy. Gilead and providers will need strong testing and follow-up systems. This issue could affect payer protocols and prescribing restrictions.
Yeztugo is not a biologic. Biosimilar competition is therefore not the relevant threat. The material long-term threats are generic or alternative small-molecule products, competing injectables, new capsid inhibitors and patent challenges.
What patents protect Yeztugo?
Yeztugo’s protection is expected to involve several patent categories:
- Lenacapavir composition-of-matter patents.
- Solid-state and salt-form patents.
- Injectable formulation patents.
- Long-acting delivery patents.
- Dosing and HIV prevention method-of-use patents.
- Manufacturing and purification patents.
- Combination and treatment-method patents related to HIV management.
The strongest protection is normally the composition-of-matter patent. Formulation and dosing patents can extend commercial protection but are more vulnerable to validity and infringement challenges than a core compound patent.
The relevant patent analysis must separate:
- Yeztugo prevention claims.
- Sunlenca treatment claims.
- Injectable formulation claims.
- Specific six-month dosing claims.
- Manufacturing claims that may affect generic or competing-product entry.
Publicly available approval and product materials establish the clinical and regulatory profile, but they do not by themselves establish the full terminal patent date. Exact U.S. patent expiry, patent-term adjustment, patent-term extension and Orange Book listing status should be determined from current FDA and USPTO records.
Are generic companies likely to file Paragraph IV challenges?
A Paragraph IV challenge is possible but unlikely to be commercially immediate. Generic applicants would need to address:
- The active pharmaceutical ingredient.
- The injectable formulation.
- The six-month pharmacokinetic profile.
- Administration requirements.
- Bioequivalence or comparative clinical requirements.
- Patent claims covering prevention dosing.
- Long-acting release characteristics.
The product’s complexity creates a higher barrier than a conventional oral tablet. A generic applicant could challenge the core compound patent, formulation patents, method-of-use patents or all three. Litigation risk will increase as annual U.S. sales approach the multibillion-dollar range.
The earliest realistic generic entry date will depend on the controlling composition patent and any valid patent-term extension, not simply the FDA approval date. Yeztugo’s commercial exposure should therefore be modeled using multiple entry dates rather than a single assumed expiry.
What licensing deals affect Yeztugo’s global market?
Gilead has pursued voluntary licensing for lenacapavir to support access in lower-income countries. In October 2024, Gilead announced agreements with six generic manufacturers to supply lenacapavir for HIV prevention in 120 countries after regulatory approval and other implementation requirements (Gilead Sciences, 2024c).
The licensing structure has two effects:
- It expands potential patient volume and supports global HIV prevention targets.
- It limits revenue per patient in licensed markets and may create geographic price segmentation.
The United States, Western Europe, Japan and other high-income markets will drive the majority of commercial revenue. Licensed countries may drive the majority of public-health impact.
What are the principal risks to Yeztugo’s financial trajectory?
Reimbursement risk
A $28,218 annual list price creates pressure on Medicaid, public-health programs and commercial payers. Restrictions could delay initiation and reduce persistence.
Administration risk
Yeztugo requires healthcare-provider administration. Clinics must maintain recall systems, HIV testing, injection capacity and follow-up. The six-month schedule lowers visit frequency but increases the consequence of missed appointments.
Cannibalization risk
Gilead may shift patients from Descovy or other oral PrEP products into Yeztugo. Gross Yeztugo sales could therefore overstate the company’s incremental HIV prevention growth.
Competitive risk
ViiV can respond through Apretude pricing, contracting, service programs or next-generation long-acting products. Oral generic PrEP will remain widely available.
Resistance and safety risk
The long pharmacokinetic tail creates a clinical-management issue if HIV infection develops after a missed dose or incomplete testing. Any signal involving resistance or delayed diagnosis could affect prescribing and payer coverage.
Policy risk
Government procurement and HIV prevention funding are sensitive to budget conditions. Public-sector programs may prioritize lower-cost oral PrEP even when the clinical value of long-acting dosing is higher.
Key Takeaways
- Yeztugo is a twice-yearly lenacapavir injection for HIV PrEP developed by Gilead Sciences.
- Its core commercial advantage is the six-month dosing interval.
- Its primary competitors are generic TDF/FTC, Descovy and ViiV’s Apretude.
- Gilead’s U.S. list price is approximately $28,218 annually before discounts and rebates.
- A base-case U.S. revenue opportunity is approximately $2.4 billion to $3.4 billion annually if 200,000 patients receive treatment at estimated net revenue of $12,000 to $17,000 per year.
- The principal risks are reimbursement restrictions, injection logistics, resistance management and competition from lower-cost oral PrEP.
- Global licensing can expand access while reducing per-patient revenue outside high-income markets.
- Patent value will depend on the strength and expiry of lenacapavir composition, formulation, dosing and manufacturing claims.
- Generic entry is likely to require complex formulation and bioequivalence work, making immediate substitution less likely than for oral PrEP.
FAQs
How often is Yeztugo administered?
Yeztugo is administered by subcutaneous injection every six months after the initiation regimen.
Is Yeztugo a treatment for HIV?
No. Yeztugo is approved for HIV prevention in people who are HIV-negative. Sunlenca is the lenacapavir product used for treatment of multidrug-resistant HIV in combination with other antiretroviral medicines.
Can Yeztugo replace condoms?
Yeztugo prevents sexually acquired HIV but does not prevent other sexually transmitted infections. Its use does not eliminate the need for HIV testing or other prevention measures.
Will Yeztugo be available through Medicaid and public-health clinics?
Coverage will depend on federal and state Medicaid policies, rebates, public-health procurement terms and implementation protocols. Public clinics are likely to be important distribution points because they already provide HIV testing and prevention services.
What is the biggest commercial threat to Yeztugo?
The largest threat is a combination of payer price restrictions and strong generic oral PrEP competition. Apretude is the most direct branded competitor, but generic TDF/FTC will exert the greatest pricing pressure.
References
- Gilead Sciences, Inc. (2024a). Gilead presents PURPOSE 1 results for twice-yearly lenacapavir for HIV prevention.
- Gilead Sciences, Inc. (2024b). Gilead announces PURPOSE 2 results for twice-yearly lenacapavir for HIV prevention.
- Gilead Sciences, Inc. (2024c). Gilead announces voluntary licensing agreements for twice-yearly lenacapavir for HIV prevention in 120 countries.
- Gilead Sciences, Inc. (2025). Gilead announces U.S. availability and pricing for Yeztugo.
- U.S. Food and Drug Administration. (2025). Yeztugo prescribing information and FDA approval materials.
